Analysts' Actions: ORCL, MTB, COF

NEW YORK (TheStreet) -- CHANGE IN RATINGS

Assurant (AIZ) downgraded at BofA/Merrill from Buy to Neutral, Bank of America/Merrill Lynch said. Company is facing increased regulatory risk. $45 price target.

Armstrong World (AWI) downgraded at Stifel from Buy to Hold, Stifel Nicolaus said. Valuation call.

BB&T (BBT) downgraded at Guggenheim from Buy to Hold, Guggenheim said. Valuation call, based on a $34 price target.

Blackrock (BLK) downgraded at Morgan Stanley from Overweight to Equal-weight, Morgan Stanley said. Valuation call, based on a $224 price target.

Capital One (COF) upgraded at Guggenheim from Neutral to Buy, Guggenheim said. $67 price target. Recent acquisitions should add to earnings.

Cintas (CTAS) downgraded at Baird from Outperform to Neutral, Robert Baird said. Valuation call, based on a $45 price target.

Cloud Peak Energy (CLD) downgraded to hold at TheStreet Ratings.

Edgewater Technology (EDGW) downgraded to hold at TheStreet Ratings.

Hudson City (HCBK) rated new Buy at Compass Point. Valuation call, based on an $8.50 price target.

LinkedIn (LNKD) upgraded at Goldman from Neutral to Buy, Goldman Sachs said. $135 price target. Estimates also boosted, given higher operating metrics.

Allscripts (MDRX) downgraded at JP Morgan from Overweight to Neutral, JP Morgan said. Performance has lagged since the Eclipsys merger.

MicroStrategy (MSTR) rated new Buy at Think. $160 price target. License business is likely to show accelerated growth over the next couple of years.

M&T Bank (MTB) downgraded at Guggenheim from Buy to Neutral, Guggenheim said. $96 price target. Company is less attractive in an improving economy.

Nisource (NI) upgraded at Keybanc from Hold to Buy, Keybanc said. $26.50 price target. Stock is attractive, based on a sum-of-the-parts valuation.

Regions Financial (RF) upgraded at Guggenheim from Neutral to Buy, Guggenheim said. Valuation call, based on a $9 price target.

Royal Gold (RGLD) upgraded at National Bank Financial to Outperform from Sector Perform, National Bank Financial. $82 price target. Recent sell off overdone.

Silicon Laboratories (SLAB) upgraded at UBS to Buy from Neutral, UBS said. $50 price target. Expect new CEO to raise R&D efficiency.

US Silica (SLCA) rated new Buy at Dahlman. $25 price target. Company is leveraged to growth in the fracture proppant market.

Suntrust (STI) downgraded at Guggenheim from Buy to Neutral, Guggenheim said. Valuation call, based on a $26 price target.

STOCK COMMENTS / EPS CHANGES

Amedisys (AMED) numbers raised at Jefferies. Shares of AMED now seen reaching $16.50, Jefferies said. Estimates also raised to reflect benefit of agency rationalization efforts. Hold rating.

1 2 3 Next › Last »